Literature DB >> 25675280

The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.

Adi F Gazdar1, Trisha K Savage, Jane E Johnson, Anton Berns, Julien Sage, R Ilona Linnoila, David MacPherson, David G McFadden, Anna Farago, Tyler Jacks, William D Travis, Elisabeth Brambilla.   

Abstract

INTRODUCTION: Because small-cell lung carcinomas (SCLC) are seldom resected, human materials for study are limited. Thus, genetically engineered mouse models (GEMMs) for SCLC and other high-grade lung neuroendocrine (NE) carcinomas are crucial for translational research.
METHODS: The pathologies of five GEMMs were studied in detail and consensus diagnoses reached by four lung cancer pathology experts. Hematoxylin and Eosin and immunostained slides of over 100 mice were obtained from the originating and other laboratories and digitalized. The GEMMs included the original Rb/p53 double knockout (Berns Laboratory) and triple knockouts from the Sage, MacPherson, and Jacks laboratories (double knockout model plus loss of p130 [Sage laboratory] or loss of Pten [MacPherson and Jacks laboratories]). In addition, a GEMM with constitutive co-expression of SV40 large T antigen and Ascl1 under the Scgb1a1 promoter from the Linnoila laboratory were included.
RESULTS: The lung tumors in all of the models had common as well as distinct pathological features. All three conditional knockout models resulted in multiple pulmonary tumors arising mainly from the central compartment (large bronchi) with foci of in situ carcinoma and NE cell hyperplasia. They consisted of inter- and intra-tumor mixtures of SCLC and large-cell NE cell carcinoma in varying proportions. Occasional adeno- or large-cell carcinomas were also seen. Extensive vascular and lymphatic invasion and metastases to the mediastinum and liver were noted, mainly of SCLC histology. In the Rb/p53/Pten triple knockout model from the MacPherson and Jacks laboratories and in the constitutive SV40/T antigen model many peripherally arising non-small-cell lung carcinoma tumors having varying degrees of NE marker expression were present (non-small-cell lung carcinoma-NE tumors). The resultant histological phenotypes were influenced by the introduction of specific genetic alterations, by inactivation of one or both alleles of specific genes, by time from Cre activation and by targeting of lung cells or NE cell subpopulations.
CONCLUSION: The five GEMM models studied are representative for the entire spectrum of human high-grade NE carcinomas and are also useful for the study of multistage pathogenesis and the metastatic properties of these tumors. They represent one of the most advanced forms of currently available GEMM models for the study of human cancer.

Entities:  

Mesh:

Year:  2015        PMID: 25675280      PMCID: PMC4523224          DOI: 10.1097/JTO.0000000000000459

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  44 in total

Review 1.  Lung cancer.

Authors:  Roy S Herbst; John V Heymach; Scott M Lippman
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

Review 2.  Lung tumours with neuroendocrine differentiation.

Authors:  William D Travis
Journal:  Eur J Cancer       Date:  2009-09       Impact factor: 9.162

3.  Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.

Authors:  Diana N Ionescu; Diana Treaba; Cyril B Gilks; Samuel Leung; Daniel Renouf; Janessa Laskin; Richard Wood-Baker; Allen M Gown
Journal:  Am J Surg Pathol       Date:  2007-01       Impact factor: 6.394

Review 4.  Mouse models for human lung cancer.

Authors:  Ralph Meuwissen; Anton Berns
Journal:  Genes Dev       Date:  2005-03-15       Impact factor: 11.361

5.  Mouse lung neuroendocrine carcinomas: distinct morphologies, same transcription factors.

Authors:  R Ilona Linnoila; Xu Naizhen; Ralph Meuwissen; Anton Berns; Franco J DeMayo
Journal:  Exp Lung Res       Date:  2005 Jan-Feb       Impact factor: 2.459

6.  Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

Authors:  Bethany E Schaffer; Kwon-Sik Park; Gloria Yiu; Jamie F Conklin; Chenwei Lin; Deborah L Burkhart; Anthony N Karnezis; E Alejandro Sweet-Cordero; Julien Sage
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 7.  Lung cancer in never smokers--a different disease.

Authors:  Sophie Sun; Joan H Schiller; Adi F Gazdar
Journal:  Nat Rev Cancer       Date:  2007-10       Impact factor: 60.716

8.  The frequency of neuroendocrine cell hyperplasia in patients with pulmonary neuroendocrine tumours and non-neuroendocrine cell carcinomas.

Authors:  Selim M H Rizvi; Joseph Goodwill; Eric Lim; Yoong K Yap; Athol U Wells; David M Hansell; Peter Davis; Abdel-Ghani Selim; Syed Abdel-Ghani; Peter Goldstraw; Andrew G Nicholson
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

9.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.

Authors:  Michel DuPage; Alison L Dooley; Tyler Jacks
Journal:  Nat Protoc       Date:  2009-06-25       Impact factor: 13.491

10.  A small-cell lung cancer genome with complex signatures of tobacco exposure.

Authors:  Erin D Pleasance; Philip J Stephens; Sarah O'Meara; David J McBride; Alison Meynert; David Jones; Meng-Lay Lin; David Beare; King Wai Lau; Chris Greenman; Ignacio Varela; Serena Nik-Zainal; Helen R Davies; Gonzalo R Ordoñez; Laura J Mudie; Calli Latimer; Sarah Edkins; Lucy Stebbings; Lina Chen; Mingming Jia; Catherine Leroy; John Marshall; Andrew Menzies; Adam Butler; Jon W Teague; Jonathon Mangion; Yongming A Sun; Stephen F McLaughlin; Heather E Peckham; Eric F Tsung; Gina L Costa; Clarence C Lee; John D Minna; Adi Gazdar; Ewan Birney; Michael D Rhodes; Kevin J McKernan; Michael R Stratton; P Andrew Futreal; Peter J Campbell
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

View more
  49 in total

Review 1.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

2.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Authors:  Gurkan Mollaoglu; Matthew R Guthrie; Stefanie Böhm; Johannes Brägelmann; Ismail Can; Paul M Ballieu; Annika Marx; Julie George; Christine Heinen; Milind D Chalishazar; Haixia Cheng; Abbie S Ireland; Kendall E Denning; Anandaroop Mukhopadhyay; Jeffery M Vahrenkamp; Kristofer C Berrett; Timothy L Mosbruger; Jun Wang; Jessica L Kohan; Mohamed E Salama; Benjamin L Witt; Martin Peifer; Roman K Thomas; Jason Gertz; Jane E Johnson; Adi F Gazdar; Robert J Wechsler-Reya; Martin L Sos; Trudy G Oliver
Journal:  Cancer Cell       Date:  2017-01-12       Impact factor: 31.743

Review 3.  Family matters: How MYC family oncogenes impact small cell lung cancer.

Authors:  Johannes Brägelmann; Stefanie Böhm; Matthew R Guthrie; Gurkan Mollaoglu; Trudy G Oliver; Martin L Sos
Journal:  Cell Cycle       Date:  2017-07-24       Impact factor: 4.534

Review 4.  Small cell lung cancer: will recent progress lead to improved outcomes?

Authors:  M Catherine Pietanza; Lauren Averett Byers; John D Minna; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

5.  TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.

Authors:  Nagako Akeno; Alisa L Reece; Melissa Callahan; Ashley L Miller; Rebecca G Kim; Diana He; Adam Lane; Jonathan S Moulton; Kathryn A Wikenheiser-Brokamp
Journal:  Mol Cancer Ther       Date:  2017-08-28       Impact factor: 6.261

Review 6.  Unravelling the biology of SCLC: implications for therapy.

Authors:  Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2017-05-23       Impact factor: 66.675

Review 7.  From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers.

Authors:  Adi F Gazdar; Fred R Hirsch; John D Minna
Journal:  J Thorac Oncol       Date:  2015-12-24       Impact factor: 15.609

8.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.

Authors:  Mark D Borromeo; Trisha K Savage; Rahul K Kollipara; Min He; Alexander Augustyn; Jihan K Osborne; Luc Girard; John D Minna; Adi F Gazdar; Melanie H Cobb; Jane E Johnson
Journal:  Cell Rep       Date:  2016-07-21       Impact factor: 9.423

Review 9.  Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?

Authors:  Sandra Cristea; Julien Sage
Journal:  J Thorac Oncol       Date:  2016-04-29       Impact factor: 15.609

10.  New models of large-cell neuroendocrine carcinoma and small-cell lung carcinoma.

Authors:  Mirentxu Santos
Journal:  Mol Cell Oncol       Date:  2020-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.